Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy (NCT04026178), a na phase 4 study. The primary outcome is Evaluate the Immunogenicity Associated With Daily Subcutaneous (SC) Metreleptin Treatment in Patients With Congenital Generalized Lipodystrophy (CGL) or Acquired Generalized Lipodystrophy (AGL)..

2. Clinical Question

The study asks whether daily subcutaneous metreleptin treatment is associated with anti-metreleptin or anti-human leptin binding antidrug antibodies over time in patients with congenital generalized lipodystrophy (CGL) or acquired generalized lipodystrophy (AGL). It also describes neutralizing antibody (NAb) activity to metreleptin, including activity assessed with a cell-based method and receptor-blocking activity in antibody-positive samples.

This is an immunogenicity question, rather than a comparative efficacy question. Antibody measurements describe immune responses associated with exposure; they do not, by themselves, establish clinical benefit or harm. The registry also lists safety and tolerability in relation to antibody findings as a secondary objective. However, numerical results linking antibody status to clinical safety outcomes are not reported in the registry record.

3. Trial Design

This is a completed, multicenter, open-label Phase 4 study of metreleptin in patients with generalized lipodystrophy. The official title describes a 36-month study, and the primary outcome timeframe is also 36 months. The registry records a start date of 2018-11-14 and a primary completion date of 2024-10-31.

The study uses a single-group design. The registry gives no allocation to comparative groups and no masking. Participants received metreleptin; there is no separate control group against which to estimate a between-group treatment effect. Consequently, changes or antibody findings during follow-up cannot be separated from the passage of time, participant characteristics, or other influences using a randomized comparison in this study.

The recorded enrollment is 11. That figure describes enrollment, not necessarily the number with evaluable measurements at every assessment. The number analyzed at each time point and the completeness of follow-up are not reported in the registry record. The protocol’s sample-size justification is also not reported in the registry record.

The primary outcome concerns anti-metreleptin and anti-human leptin binding antibody titers over time, along with categories of in vitro cell-based NAb activity and receptor-blocking assay titers among antibody-positive samples. The registry states that only ADA-positive participants were analyzed for neutralizing activity. It lists additional objectives related to measuring in vitro NAb activity and evaluating safety and tolerability in relation to antibody and NAb findings.

The registry does not report a statistical analysis plan, an interim analysis approach, or a detailed schedule of assessment visits. These design details should not be inferred from the stated study duration or the outcome description.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: At Screening, consenting patients were assessed to ensure that they met eligibility criteria. The informed consent and health insurance portability and accountability act Authorization forms were signed prior to performing any Protocol-required procedures. The assessments conducted at the Screening Visit. When all Screening results were available, individuals were notified of their eligibility status.

Overall Study

Analysis population for the primary outcome, as defined in the registry: Only ADA positive participants were analysed for neutralizing activity.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Evaluate the Immunogenicity Associated With Daily Subcutaneous (SC) Metreleptin Treatment in Patients With Congenital Generalized Lipodystrophy (CGL) or Acquired Generalized Lipodystrophy (AGL)., measured over 36 months.

The primary endpoint describes immunogenicity during metreleptin treatment. It includes anti-metreleptin and anti-human leptin binding antidrug antibody titers over time, as well as categories of in vitro cell-based neutralizing antibody activity. For ADA-positive samples, it also includes titers from a receptor-blocking NAb assay. The stated unit is participants, and the outcome is described as a count of participants.

Binding antibodies indicate that antibodies directed against metreleptin or human leptin were detected by the relevant measurement. Neutralizing assays address a different question: whether antibody activity can interfere with a biological action in an in vitro assay. The registry’s endpoint description therefore covers both binding and functional assay findings. A laboratory finding should not automatically be interpreted as a clinical consequence; the registry does not provide a numerical link between these measurements and clinical outcomes.

Repeated assessment over time can describe whether antibody findings are present at different points during treatment. For neutralizing activity, however, the registry specifies that only ADA-positive participants were analyzed. Those results therefore concern a selected subset, rather than every participant enrolled in the study.

Although the endpoint is defined in the registry, numerical primary outcome results are not reported in the registry record. The record does not give antibody counts, titers, category distributions, or the number with evaluable measurements at each assessment. The extent to which the endpoint was observed across the planned timeframe therefore cannot be determined from the available registry information.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry identifies the primary outcome as a count of participants and describes antibody titers and neutralizing activity over time. It does not report the numerical outcome values or a detailed statistical analysis plan. The concepts below explain how such measurements are generally interpreted; they do not establish which specific procedures the investigators used.

What does a participant count describe?

General statistical context: a count records how many people meet a defined outcome criterion. To interpret a count, readers need to know its denominator and the criterion used to classify participants. For a longitudinal outcome, the denominator can differ across assessment times if participants miss visits or lack usable specimens. The registry states an enrollment of 11 but does not report the number analyzed at each assessment. A count alone would not reveal the proportion of enrolled participants with an outcome unless the relevant denominator were also known; no such primary outcome counts are reported in the registry record.

How do binding and neutralizing antibody measures differ?

The primary endpoint covers binding antibody titers against metreleptin and human leptin, and in vitro measures of neutralizing activity. These are related but distinct forms of measurement. A binding assay detects antibody binding under the assay conditions. A neutralizing assay evaluates activity in a laboratory system designed to assess interference with a biological action. The receptor-blocking assay is described for ADA-positive samples. Laboratory activity is not itself a clinical outcome, and the registry does not report a validated relationship between the assay results and clinical consequences.

Titer data can be reported as levels or categories, but the registry record does not provide the values, category definitions, or summary statistics. It would therefore be inappropriate to infer the distribution, direction of change, or clinical importance of the antibody findings. The record also does not state how values below an assay’s detection limit, if any, were handled.

Why does the analysis population matter?

General statistical context: an analysis population defines which participants contribute to a particular result. The registry explicitly states that only ADA-positive participants were analyzed for neutralizing activity. This conditional analysis addresses neutralizing activity among participants with detected binding antibodies; it does not describe neutralizing activity across the full enrolled population. It also means that interpretation depends on how ADA positivity was defined and how many participants met that definition. The threshold and the number of positive participants are not reported in the registry record.

Different outcome measures may also have different available data. A participant could have a binding antibody result but no usable neutralizing assay result, or could lack a measurement at a particular time. The registry does not describe missing-data handling, exclusions, or the analysis population for each primary measure. These details are needed to assess whether reported counts represent all enrolled participants, those with available specimens, or another defined group.

What can a confidence interval tell a reader?

General statistical context: a confidence interval expresses the uncertainty around an estimated quantity under a statistical model. A narrower interval generally indicates greater precision for that estimate, while a wider interval indicates more uncertainty. The interval does not remove limitations in study design, correct bias automatically, or show that an association is causal. No confidence intervals for the primary immunogenicity outcome are reported in the registry record, so precision cannot be assessed from those results.

Why can repeated measurements require careful analysis?

General statistical context: observations from the same participant over time are usually related rather than independent. Analyses of repeated measurements may need to account for that within-participant relationship, and should describe how incomplete follow-up is handled. A summary at each time point and a model of change over time answer different questions. The registry describes measurements over time but does not report a model, an analysis schedule, or methods for accounting for repeated measurements. No particular longitudinal method should be attributed to the study based on the endpoint wording alone.

How should planning calculations be distinguished from results?

General statistical context: a sample-size calculation estimates the information a future design might need under stated assumptions. It is not an observed trial result and should not be presented as observed power. The registry’s planning illustration is described as using a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation, with the effect to detect expressed as a fraction of the observed effect. Those are illustration assumptions, not a reported description of the single-group trial’s design. The registry does not report the trial’s own sample-size justification or statistical plan.

For a binary outcome, a count can be easy to read but may be difficult to compare without a clearly defined denominator and assessment period. For antibody titers, the measurement scale and distribution also matter. General statistical context: strongly skewed measurements can make a mean an incomplete description, and over-dispersion—variation greater than a model expects—can make standard errors and confidence intervals too optimistic if the model does not account for it. The registry does not report enough numerical detail to determine whether either issue arose or how it was addressed.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists 5 outcome measures and 0 analyses in its structured record. It describes a primary immunogenicity outcome and secondary objectives involving methods for measuring in vitro NAb activity and safety and tolerability in relation to antibody findings. The registry record does not report a testing hierarchy, a multiplicity adjustment, or a statistical plan for deciding which analyses would be considered confirmatory.

General statistical context: when multiple outcomes, time points, or tests are examined, the chance of at least one apparently notable result can increase if every result is interpreted independently. A prespecified hierarchy or adjustment can help make interpretation more transparent. Without a reported plan, it is not possible to determine whether or how multiplicity was addressed. The number of listed outcomes alone does not reveal how many formal statistical tests were performed.

Missing-data methods are not reported in the registry record. The enrollment figure does not establish how many participants contributed to each antibody measurement or whether measurements were available throughout the 36-month timeframe. The record does not describe imputation, exclusion rules, sensitivity analyses, or reasons for missing measurements. These omissions limit assessment of whether available observations represent the intended study population.

The analysis population is specified only in part: neutralizing activity was analyzed among ADA-positive participants. The definition of ADA positivity, the count meeting that definition, and the population used for each other endpoint are not reported in the registry record. Consequently, findings for neutralizing activity, even if numerical results were available, would need to be interpreted as conditional on antibody positivity rather than as results for all enrolled participants.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: covid-19 (9.1%), autoimmune hepatitis (9.1%), pancreatitis relapsing (9.1%), osteomyelitis (9.1%), sepsis (9.1%).

The registry’s adverse-event summary records 7 affected among 11 at risk for the serious-event measure, and 11 affected among 11 at risk for the other adverse-event measure. It also records 1 death. These are safety summaries for the metreleptin group; they do not establish that the treatment caused the events. The registry record does not report event-level timing, duration, or causal assessments alongside these summary figures.

The serious-event terms listed are COVID-19, autoimmune hepatitis, relapsing pancreatitis, osteomyelitis, sepsis, and spontaneous abortion. Each is recorded at 9.1%. These term-level percentages should be read as the registry lists them, not as evidence that the events were treatment-related or as a complete account of each participant’s clinical course. The record does not state the event-specific observation period or provide further detail on severity, recurrence, or attribution.

Adverse-event summaries can use different definitions and populations. The registry’s “at risk” figures indicate the denominator recorded for each measure, but the record does not explain the detailed event-collection rules in this summary. The serious-event and other-event figures should therefore be kept separate rather than combined. No total across event terms is calculated, since the registry does not establish whether terms could occur in the same participant.

12. What the Result Does, and Does Not, Mean

The study addresses an important measurement question: what binding and neutralizing antibody findings are observed during daily metreleptin treatment in patients with CGL or AGL? Its single-group, open-label design is suited to describing observations within the treated group, but it does not provide a randomized comparison with another treatment or a no-treatment condition.

The registry record defines the primary outcome and the population for the neutralizing activity analysis, but does not report numerical primary results. It therefore does not establish the frequency or course of binding antibodies, the distribution of neutralizing activity, or the precision of those findings. This absence should not be interpreted as a finding of no antibodies or no neutralizing activity; the results are simply not reported in the registry record.

Even if antibody results were available, laboratory measurements and clinical outcomes are not interchangeable. An in vitro neutralizing result describes activity in an assay. It does not by itself show a clinical effect. The registry lists safety and tolerability in relation to antibody status as an objective, but does not report the numerical analysis needed to assess that relationship.

The adverse-event summary supplies descriptive safety counts and listed event terms. It does not establish causality. With no separate comparator group in this study, the event figures cannot show whether the observed events occurred more or less often than they would under an alternative condition.

Accordingly, the record documents the study’s purpose, design, endpoint definitions, and selected safety summaries. It does not support a conclusion about comparative effectiveness, the clinical significance of antibody findings, or the causal role of treatment in adverse events. Those questions require results and analyses that are not reported in the registry record.

13. Why This Trial Matters Statistically

Immunogenicity studies bring together laboratory measurements and clinical safety questions. Binding antibodies and neutralizing activity are not the same endpoint, and the registry’s description makes that distinction explicit. Reading them separately helps avoid treating any detectable antibody result as equivalent to a demonstrated clinical effect.

The analysis population also matters. Neutralizing activity was assessed only among ADA-positive participants. This is a conditional question about a subset defined by antibody status, not a population-wide estimate. The number of participants meeting that definition and the corresponding numerical results are not reported in the registry record, so the scope and precision of that analysis cannot be evaluated.

The study’s single-group design is another important statistical feature. It can describe findings during treatment, but it cannot produce a randomized estimate of how those findings or safety outcomes compare with a different treatment condition. The open-label design and absence of a separate comparator should therefore shape interpretation of any within-group observations.

Finally, a clearly stated endpoint is not the same as a fully reported result. The registry identifies antibody titers and neutralizing activity over time, yet does not report their numerical values. Without counts, denominators at each assessment, or uncertainty estimates, readers cannot judge the magnitude or precision of the immunogenicity findings. That distinction—between what a study set out to measure and what the record reports—is central to careful interpretation.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several study-specific limitations follow from the registry record. The single-group design has no separate comparator, so it cannot isolate treatment effects from other influences or support a randomized between-group comparison. The study is open label, and masking is recorded as none. These features are especially relevant when interpreting safety events and changes observed over time.

The record gives an enrollment of 11 but does not report the number contributing to each antibody assessment. It does not describe missing specimens, withdrawals, visit completion, or the handling of unavailable measurements. As a result, the denominator and representativeness of any time-specific result cannot be checked from the registry information.

The primary outcome is described, but numerical antibody results are not reported in the registry record. The definitions of positivity and antibody categories, assay thresholds, and summary methods are also not reported. The neutralizing activity analysis is restricted to ADA-positive participants, but the number of participants in that subset is not given.

The registry does not report confidence intervals, p-values, a longitudinal model, a multiplicity plan, or the trial’s sample-size justification. It also does not provide detailed event-level timing or causal assessments with the adverse-event summary. These gaps limit evaluation of precision, analytic choices, and the relationship between antibody findings and safety outcomes. No conclusion about an unreported result or analysis should be inferred from the study’s stated objectives alone.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy — NCT04026178.
• Registry record last updated 2025-11-26; status last verified 2025-11.
• Results first posted 2025-11-26.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry records NCT04026178 as a completed, multicenter, open-label Phase 4 study titled “Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy.” The study evaluated daily subcutaneous metreleptin in patients with CGL or AGL over a stated timeframe of 36 months. Recorded enrollment was 11; the study start date was 2018-11-14 and primary completion date was 2024-10-31.

The primary outcome concerns anti-metreleptin and anti-human leptin binding antibody titers over time, along with in vitro neutralizing activity. Only ADA-positive participants were analyzed for neutralizing activity. Numerical primary outcome findings and detailed statistical methods are not reported in the registry record.

The safety summary records serious and other adverse-event measures and lists serious-event terms, along with 1 death. The single-group design has no separate comparator, so the safety figures are descriptive and do not establish causation. The record supports description of study intent and design, but not a comparative treatment conclusion.